You are here

Award Data

For best search results, use the search terms first and then apply the filters
Reset

The Award database is continually updated throughout the year. As a result, data for FY23 is not expected to be complete until September, 2024.

Download all SBIR.gov award data either with award abstracts (290MB) or without award abstracts (65MB). A data dictionary and additional information is located on the Data Resource Page. Files are refreshed monthly.

The SBIR.gov award data files now contain the required fields to calculate award timeliness for individual awards or for an agency or branch. Additional information on calculating award timeliness is available on the Data Resource Page.

Displaying 201461 - 201470 of 205243 results
  1. Vaccine Adjuvant for Rapid Tolerance Induction in Allergy Patients

    SBC: TRIA BIOSCIENCE CORP.            Topic: NIAID

    DESCRIPTION (provided by applicant): Allergy is a major cause of illness and disability with an estimated 40-50 million people afflicted in the US alone. AIT provides long-term benefits for the patient and its need for optimization creates a compelling business opportunity. There is a very strong rationale to develop GLA for allergy based on its superior drug profile to MPL, a related TLR4 agonist ...

    SBIR Phase I 2013 Department of Health and Human ServicesNational Institutes of Health
  2. HUMAN PROTEOLYTIC FOR IgA NEPHROPATHY

    SBC: CYTODESIGN, INC.            Topic: NIAID

    DESCRIPTION (provided by applicant): Immunoglobulin A nephropathy (IgAN) is the most common form of glomerulonephritis worldwide. The disease is characterized by progressive deposition of abnormal immune complexes of polyclonal IgA in the mesangia of the glomeruli, causing chronic inflammation and progressive damage to the kidneys, evolving into end-stage renal disease in up to 40% of cases, for w ...

    SBIR Phase I 2013 Department of Health and Human ServicesNational Institutes of Health
  3. College Alcohol Assessment and Intervention Training Simulation

    SBC: NURIX, INC.            Topic: NIAID

    DESCRIPTION (provided by applicant): ZAP-70 is a cytoplasmic protein tyrosine kinase that plays a critical function in T cell antigen receptor (TCR) signaling and in most aspects of T cell biology. ZAP-70 is an attractive therapeutic target for treatment of prevalent human T-cell dependent autoimmune diseases (e.g. rheumatoid arthritis, lupus, multiple sclerosis, psoriasis) and in allogenic transp ...

    SBIR Phase I 2013 Department of Health and Human ServicesNational Institutes of Health
  4. Medical Images, HTML5, and Clinical Trial Remote Collaboration

    SBC: MICROBIOTIX, INC.            Topic: NIAID

    DESCRIPTION: Pseudomonas aeruginosa is a common and extremely virulent cause of serious infections in immune- compromised/suppressed patients (e.g., HIV and cancer), cystic fibrosis patients, and those on mechanical ventilation or with burn wounds. Related clinically important Gram-negative [Gr(-)] nonfermenters include species of the genera Burkholderia, Acinetobacter, and Stenotrophomonas, whic ...

    SBIR Phase I 2013 Department of Health and Human ServicesNational Institutes of Health
  5. Software for improved accuracy and rapid tracking of kinematics from dynamic Xray

    SBC: TECHNOVAX INC            Topic: NIAID

    DESCRIPTION (provided by applicant): We propose to develop a broadly neutralizing, possibly universal influenza vaccine based on virus-like particles (VLPs) displaying remodeled HA molecules which present otherwise cryptic epitopes. These remodeled HAs will be expressed in forms lacking the dominant hypervariable epitopes and instead display distinctly conserved subdominant antigenic sites known t ...

    SBIR Phase I 2013 Department of Health and Human ServicesNational Institutes of Health
  6. Selective MRTF/SRF-Transcription Inhibitors: Novel Anti-fibrotics for IPF

    SBC: Promiliad Biopharma Incorporated            Topic: NIAID

    DESCRIPTION: Antibiotic resistance among common bacterial pathogens is a serious public health problem as it compromises our ability to treat infectious disease. The resistance problem is compounded by the relative lack of discovery of new antibiotics, especially those with novel mechanisms of action. Over the past several years Promiliad Biopharma has been developing new inhibitors that target ...

    SBIR Phase I 2013 Department of Health and Human ServicesNational Institutes of Health
  7. Evaluation of a new class of molecules for treating MRSA infective endocarditis

    SBC: Aradigm Corporation            Topic: NIAID

    DESCRIPTION (provided by applicant): Lung infections by Mycobacterium avium and Mycobacterium abscessus are increasing in incidence. Diseases caused by both Mycobacteria are common in patients with chronic lung conditions, such as cystic fibrosis (CF), non-CF bronchiectasis and emphysema. In patients with AIDS, the M. avium infection is disseminated. The current clinical paradigm is to treat patie ...

    SBIR Phase I 2013 Department of Health and Human ServicesNational Institutes of Health
  8. Digital Microfluidic Sample Preparation of Blood for Mass Spectrometry

    SBC: Amplyx Pharmaceuticals, Inc.            Topic: NIAID

    DESCRIPTION (provided by applicant): Invasive aspergillosis (IA), caused by the fungus Aspergillus fumigatus, is associated with mortality rates of 40- 50%. In response to the lack of effective treatments, the Infectious Diseases Society of America highlighted A. fumigatus as one of only six pathogens for which it mandated that a substantive breakthrough is urgently needed . IA accounts for the l ...

    SBIR Phase I 2013 Department of Health and Human ServicesNational Institutes of Health
  9. Synthesis and Characterization of Polymeric Antioxidant microparticles for the pr

    SBC: ARISAN THERAPEUTICS INC            Topic: NIAID

    DESCRIPTION (provided by applicant): Influenza A viruses are a major global health concern. Despite annual vaccination programs in the US, 10-15% of the population is infected annually accounting for an estimated 36,000 deaths and 200,000 hospitalizations.Two classes of antiviral drugs have been approved for influenza prophylaxis and treatment. Alarmingly, the past decade has witnessed the emergen ...

    SBIR Phase I 2013 Department of Health and Human ServicesNational Institutes of Health
  10. Point of Care Device for Molecular Detection of HIV

    SBC: ADVANCED GENETIC SYSTEMS, INC.            Topic: NIAID

    DESCRIPTION (provided by applicant): There is a significant need for novel HIV therapies given the emergence of viruses resistant to existing drug regimens. The Rev-RRE protein-RNA interaction in HIV plays an essential role in the transport of viral mRNA from the nucleus to the cytoplasm where it can be translated or packaged. Previously we identified the thienopyridine scaffold that inhibited HIV ...

    SBIR Phase I 2013 Department of Health and Human ServicesNational Institutes of Health
US Flag An Official Website of the United States Government